$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000143774922020131 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$16.10M	$16.60M	$13.56M
YoY Change	41.81%	27.41%	81.22%
Cost Of Revenue	$2.020M	$1.846M	$1.525M
YoY Change	62.38%	29.36%	70.01%
Gross Profit	$14.08M	$14.76M	$12.04M
YoY Change	39.28%	27.17%	82.74%
Gross Profit Margin	87.45%	88.88%	88.76%
Selling, General & Admin	$19.07M	$20.83M	$21.30M
YoY Change	-11.81%	-6.6%	-4.01%
% of Gross Profit	135.48%	141.16%	176.92%
Research & Development	$13.09M	$12.64M	$12.70M
YoY Change	9.81%	4.26%	20.76%
% of Gross Profit	93.01%	85.65%	105.46%
Depreciation & Amortization	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
% of Gross Profit	1.42%	1.36%	1.66%
Operating Expenses	$32.16M	$33.47M	$34.00M
YoY Change	-4.12%	-2.77%	3.96%
Operating Profit	-$18.09M	-$18.72M	-$21.96M
YoY Change	-22.84%	-18.0%	-15.92%
Interest Expense	-$2.253M	-$2.213M	-$280.0K
YoY Change	-3186.3%	-2207.62%	-264.71%
% of Operating Profit
Other Income/Expense, Net	-$4.782M	-$5.731M	-$5.830M
YoY Change	-30.13%	79.54%	-58400.0%
Pretax Income	-$25.12M	-$26.66M	-$28.07M
YoY Change	-16.84%	2.89%	8.22%
Income Tax	$709.0K	$32.00K	$325.0K
% Of Pretax Income
Net Earnings	-$25.83M	-$26.69M	-$28.39M
YoY Change	-14.5%	1.79%	9.47%
Net Earnings / Revenue	-160.47%	-160.75%	-209.32%
Basic Earnings Per Share	-$1.13	-$1.18	-$1.25
Diluted Earnings Per Share	-$1.133M	-$1.176M	-$1.255M
COMMON SHARES
Basic Shares Outstanding	22.74M	22.70M	22.63M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$95.91M	$111.7M	$136.4M
YoY Change	-9.7%	-7.68%	79.75%
Cash & Equivalents	$28.69M	$80.69M	$105.4M
Short-Term Investments	$67.23M	$31.05M	$31.07M
Other Short-Term Assets	$11.39M	$11.24M	$9.825M
YoY Change	55.23%	72.11%	31.0%
Inventory	$4.862M	$5.047M	$4.756M
Prepaid Expenses
Receivables	$9.429M	$11.60M	$9.499M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$121.6M	$139.6M	$160.5M
YoY Change	-2.83%	-0.62%	72.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.519M	$1.605M	$1.777M
YoY Change	-23.21%	-19.79%	-17.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$673.0K	$674.0K
YoY Change	-100.0%	-91.88%
Other Assets	$2.471M	$1.900M	$1.572M
YoY Change	39.37%	72.26%	2281.82%
Total Long-Term Assets	$6.879M	$6.517M	$5.191M
YoY Change	-27.31%	-50.89%	19.83%
TOTAL ASSETS
Total Short-Term Assets	$121.6M	$139.6M	$160.5M
Total Long-Term Assets	$6.879M	$6.517M	$5.191M
Total Assets	$128.5M	$146.1M	$165.7M
YoY Change	-4.55%	-4.96%	70.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.545M	$2.457M	$4.234M
YoY Change	-37.32%	-49.13%	-30.54%
Accrued Expenses	$14.38M	$13.44M	$11.78M
YoY Change	-1.61%	0.46%	14.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.00M	$18.04M	$19.09M
YoY Change	-4.07%	-5.33%	12.27%
LONG-TERM LIABILITIES
Long-Term Debt	$71.87M	$71.20M	$70.80M
YoY Change
Other Long-Term Liabilities	$100.9M	$97.82M	$92.90M
YoY Change	21.17%	24.7%	2282.08%
Total Long-Term Liabilities	$71.87M	$71.20M	$70.80M
YoY Change	-13.68%	-9.24%	1715.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.00M	$18.04M	$19.09M
Total Long-Term Liabilities	$71.87M	$71.20M	$70.80M
Total Liabilities	$191.8M	$187.1M	$182.8M
YoY Change	86.05%	91.86%	773.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$548.2M	-$522.4M	-$495.7M
YoY Change	24.9%	27.82%	29.63%
Common Stock	$485.1M	$481.5M	$478.7M
YoY Change	3.13%		4.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$63.29M	-$40.91M	-$17.07M
YoY Change
Total Liabilities & Shareholders Equity	$128.5M	$146.1M	$165.7M
YoY Change	-4.55%	-4.96%	70.11%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$25.83M	-$26.69M	-$28.39M
YoY Change	-14.5%	1.79%	9.47%
Depreciation, Depletion And Amortization	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Cash From Operating Activities	-$17.61M	-$24.20M	-$24.00M
YoY Change	-4.68%	27.73%	-12.43%
INVESTING ACTIVITIES
Capital Expenditures	-$153.0K	-$63.00K	$25.00K
YoY Change	-21.13%	-4.55%	-91.29%
Acquisitions
YoY Change
Other Investing Activities	-$35.34M	-$88.00K	$13.62M
YoY Change	-425.59%	-99.71%	-11.03%
Cash From Investing Activities	-$35.49M	-$151.0K	$13.60M
YoY Change	-432.95%	-99.51%	-9.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.101M	-77.00K	$70.74M
YoY Change	-755.36%	-100.11%	1768450.0%
NET CHANGE
Cash From Operating Activities	-17.61M	-24.20M	-$24.00M
Cash From Investing Activities	-35.49M	-151.0K	$13.60M
Cash From Financing Activities	1.101M	-77.00K	$70.74M
Net Change In Cash	-52.00M	-24.43M	$60.34M
YoY Change	551.35%	-206.96%	-587.69%
FREE CASH FLOW
Cash From Operating Activities	-$17.61M	-$24.20M	-$24.00M
Capital Expenditures	-$153.0K	-$63.00K	$25.00K
Free Cash Flow	-$17.46M	-$24.14M	-$24.02M
YoY Change	-4.5%	27.84%	-13.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22727891
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22727891
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22462995
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22462995
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-26691000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-26222000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55083000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52157000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-26691000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-26222000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55083000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52157000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-17074000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	13000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-26691000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-40913000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	76491000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-26222000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	56271000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55083000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-40913000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	96355000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	58000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52157000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	56271000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38079
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1460746
	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Alexander Park Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	768-9780
	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
	dei	Trading Symbol TradingSymbol	URGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22740526
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80690000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44360000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	31048000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44779000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	811000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1226000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11595000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11717000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	5047000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4832000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10433000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7476000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	139624000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	114390000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1605000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1967000	usd
CY2022Q2	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2116000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1180000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	673000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	675000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1900000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1311000	usd
CY2022Q2	us-gaap	Assets Assets	146141000	usd
CY2021Q4	us-gaap	Assets Assets	119746000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8647000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12102000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6428000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6948000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2965000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3330000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	18040000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22380000	usd
CY2022Q2	urgn	Prepaid Forward Obligation PrepaidForwardObligation	93461000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	71196000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1515000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	usd
CY2022Q2	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2842000	usd
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2842000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	187054000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	111333000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	62000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	61000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	481485000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	475698000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-522404000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467321000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-56000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-40913000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	146141000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119746000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16604000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13032000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30168000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20517000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	1846000	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	1427000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3371000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2324000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	14758000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	11605000	usd
	us-gaap	Gross Profit GrossProfit	26797000	usd
	us-gaap	Gross Profit GrossProfit	18193000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12640000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12124000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25336000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22637000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20833000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22304000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42133000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44493000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18715000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22823000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40672000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-48937000	usd
CY2022Q2	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5833000	usd
CY2021Q2	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	3120000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	11659000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	3120000	usd
CY2022Q2	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	2239000	usd
CY2021Q2	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	-0	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	2521000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	-0	usd
CY2022Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	128000	usd
CY2021Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	33000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	126000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	212000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26659000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25910000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54726000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51845000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	312000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	357000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	312000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	13000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-98000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-31000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-226000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26678000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26320000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55114000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52383000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.18
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.34
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22703572
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22331119
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22667825
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22287037
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2823000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6046000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-98000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5772000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-31000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12241000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-226000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55083000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52157000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	449000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	401000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	265000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	8359000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	2330000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-169000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-181000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5772000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	12241000	usd
	urgn	Interest Expense Noncash InterestExpenseNoncash	403000	usd
	urgn	Interest Expense Noncash InterestExpenseNoncash	0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	483000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	469000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	480000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1457000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-122000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2465000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2958000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1944000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	444000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1026000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3454000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	319000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-520000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2781000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-704000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	195000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-574000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-652000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48195000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46346000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-0	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	41655000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13533000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	26295000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	88000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	356000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13445000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15716000	usd
	urgn	Proceeds From Prepaid Forward Arrangement Net ProceedsFromPrepaidForwardArrangementNet	0	usd
	urgn	Proceeds From Prepaid Forward Arrangement Net ProceedsFromPrepaidForwardArrangementNet	72472000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	58000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	144000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	70793000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70665000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72519000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	35915000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10457000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45586000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54090000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	81501000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64547000	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	1419000	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	-36000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> clinical development of UGN-<em style="font: inherit;">102,</em> and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> as filed with the Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 21, 2022.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color:#ffffff;">f $522.4 </span>million and $467.3 million as of <em style="font: inherit;"> June 30, 2022</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next <em style="font: inherit;">12</em> months. The Company anticipates that it will need to raise additional capital in the future. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-522400000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"/> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p>
	us-gaap	Sublease Income SubleaseIncome	112000	usd
	us-gaap	Sublease Income SubleaseIncome	112000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	19000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	112400000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p>
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	257000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	44779000	usd
CY2022Q2	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	673000	usd
CY2021Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	675000	usd
CY2022Q2	us-gaap	Investments Investments	84120000	usd
CY2021Q4	us-gaap	Investments Investments	45454000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	260000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	516000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	527000	usd
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	56000	usd
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	56000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2457000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5786000	usd
CY2022Q2	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	679000	usd
CY2021Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	497000	usd
CY2022Q2	urgn	Accrued Clinical Expense AccruedClinicalExpense	1678000	usd
CY2021Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	1377000	usd
CY2022Q2	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	875000	usd
CY2021Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1748000	usd
CY2022Q2	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2268000	usd
CY2021Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1965000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	690000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	729000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8647000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12102000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	28000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	272000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	98000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-60000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	126000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	212000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4543000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3894000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2034000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1958000	usd
CY2022Q2	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	6577000	usd
CY2021Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	5852000	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	52401000	usd
CY2022Q2	urgn	Cash Equivalent Accumulated Gross Unrealized Gain CashEquivalentAccumulatedGrossUnrealizedGain	1000	usd
CY2022Q2	urgn	Cash Equivalents Accumulated Gross Unrealized Loss CashEquivalentsAccumulatedGrossUnrealizedLoss	3000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	52399000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	31775000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	54000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	31721000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	43600000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	83447000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4280000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4193000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2675000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2226000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1605000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1967000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	usd
CY2020Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	75000000	usd
CY2021	urgn	Capitalized Closing Costs On Prepaid Forward Obligation CapitalizedClosingCostsOnPrepaidForwardObligation	2599000	usd
CY2021	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17291000	usd
CY2021	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	3979000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	11659000	usd
	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	3911000	usd
CY2022Q2	urgn	Prepaid Forward Obligation PrepaidForwardObligation	93461000	usd
CY2020Q4	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	200000	usd
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	14000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	36000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	36000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	220000	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	218000	usd
	us-gaap	Lease Cost LeaseCost	440000	usd
	us-gaap	Lease Cost LeaseCost	451000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2116000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1180000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1515000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	3615000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2445000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1861000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	135000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M28D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0993	pure
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0543	pure
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	539000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	875000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	632000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	585000	usd
CY2022Q2	urgn	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	49000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2680000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	348000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2332000	usd
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3916311
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1010573
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	121000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	251000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	49000	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	usd
CY2022Q2	urgn	Lessor Operating Lease Payment To Be Received After Year Three LessorOperatingLeasePaymentToBeReceivedAfterYearThree	0	usd
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	421000	usd
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	56000	usd
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	56000	usd
	us-gaap	Sublease Income SubleaseIncome	112000	usd
	us-gaap	Sublease Income SubleaseIncome	112000	usd
CY2022Q1	urgn	Accrued Sales Reserve AccruedSalesReserve	1708000	usd
CY2022Q2	urgn	Sales Reserve Accruals SalesReserveAccruals	5776000	usd
CY2022Q2	urgn	Sales Reserve Utilization SalesReserveUtilization	-5549000	usd
CY2022Q2	urgn	Accrued Sales Reserve AccruedSalesReserve	1935000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22700000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22500000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2823000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6046000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5772000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12241000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	14900000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M21D
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2800000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	900000	usd

Files In Submission

Name	View Source	Status
urgn-20220630_cal.xml	Edgar Link	unprocessable
0001437749-22-020131-index-headers.html	Edgar Link	pending
0001437749-22-020131-index.html	Edgar Link	pending
0001437749-22-020131.txt	Edgar Link	pending
0001437749-22-020131-xbrl.zip	Edgar Link	pending
ex_387567.htm	Edgar Link	pending
ex_387568.htm	Edgar Link	pending
ex_387569.htm	Edgar Link	pending
ex_387570.htm	Edgar Link	pending
ex_407629.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20220630.xsd	Edgar Link	pending
urgn20220630_10q.htm	Edgar Link	pending
urgn-20220630_lab.xml	Edgar Link	unprocessable
urgn-20220630_def.xml	Edgar Link	unprocessable
urgn-20220630_pre.xml	Edgar Link	unprocessable
urgn20220630_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2022 Q3 Form 10-Q Financial Statement

#000143774922020131 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2022 Q3 Form 10-Q Financial Statement

#000143774922020131 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn